Not all cancers are driven by complexity. Some are, in fact, genetically simple—but mechanistically precise. Thyroid cancer, particularly medullary and papillary subtypes, illustrates this principle with unusual clarity. At its core lies a single gene: RET proto-oncogene. RET (REarranged during Transfection) encodes a receptor tyrosine kinase physiologically expressed in neural crest–derived cells. Under normal conditions, it requires binding of GDNF-family ligands and co-receptors (GFRα) to dimerise and activate downstream pathways—primarily MAPK and PI3K–AKT—governing survival, proliferation, and differentiation. The system is tightly regulated, spatially restricted, and developmentally essential. What happens when this control is lost? 1⃣ In Medullary Thyroid Carcinoma, RET is frequently activated by germline or somatic point mutations. These mutations cluster in two functional domains: ✳️ Extracellular cysteine substitutions (e.g., C634R) promote ligand-independent dimerisation through aberrant disulfide bonding. ✳️ Intracellular kinase domain mutations (e.g., M918T) alter catalytic conformation, increasing ATP affinity and constitutive signalling. The result is continuous pathway activation without physiological input—classic oncogene behaviour. This is the molecular basis of Multiple Endocrine Neoplasia type 2, where inherited RET mutations drive a highly penetrant cancer predisposition. Here, oncogenesis is not stochastic—it is encoded in the germline, with genotype–phenotype correlations guiding clinical management, including prophylactic thyroidectomy. 2⃣ A different mechanism operates in Papillary Thyroid Carcinoma. Rather than point mutations, chromosomal rearrangements generate RET/PTC fusion genes. These fusions place the RET kinase domain under the control of constitutively active promoters and dimerisation motifs from unrelated genes (e.g., CCDC6, NCOA4). The consequence is again constitutive activation—but now through enforced oligomerisation and ectopic expression in follicular cells where RET is not normally active. Interestingly, these alterations are often mutually exclusive with other MAPK drivers (e.g., BRAF), suggesting functional redundancy at the pathway level but strict selection at the genetic level. RET-driven thyroid tumorigenesis exemplifies a fundamental principle: oncogenes do not merely accelerate proliferation—they rewire signalling logic. A receptor designed to interpret extracellular cues becomes an autonomous generator of intracellular instruction. And once signalling is uncoupled from context, tissue architecture becomes secondary to molecular determinism.